The compound is indicated for adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control. Dulaglutide is not indicated in the treatment of subjects with type 1 diabetes mellitus or patients with diabetic ketoacidosis because these problems are the result of the islet cells being unable to produce insulin and one of the actions of Dulaglutide is to stimulate functioning islet cell to produce more insulin. Dulaglutide can be used either stand-alone or in combination with other medicines for type 2 diabetes, in particular [[metformin]], [[sulfonylureas]], [[thiazolidinediones]], and [[insulin]] taken concomitantly with meals.<ref name="pmid25029955">{{cite journal |vauthors=Terauchi Y, Satoi Y, Takeuchi M, Imaoka T |title=Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study |journal=Endocr. J. |volume= 61|issue= |pages= 949–59|date=July 2014  |pmid=25029955 |doi= 10.1507/endocrj.ej14-0147|url=http://joi.jlc.jst.go.jp/DN/JST.JSTAGE/endocrj/EJ14-0147?from=PubMed |accessdate=2014-09-29}}{{primary source inline|date=May 2016}}</ref>{{primary source inline|date=May 2016}}

 
== Side effects ==

 
The most common side effects include gastrointestinal disorders, such as [[dyspepsia]], [[decreased appetite]], [[nausea]], [[vomiting]], [[abdominal pain]], [[diarrhea]].<ref name="pmid24742660">{{cite journal |vauthors=Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z |title=Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5) |journal=Diabetes Care |volume=37 |issue=8 |pages=2149–58 |date=August 2014  |pmid=24742660 |doi=10.2337/dc13-2761 |url=http://care.diabetesjournals.org/content/37/8/2149.full |accessdate=2015-03-01 |pmc=4113177}}</ref> Some patients may experience serious adverse reactions: [[acute pancreatitis]] (symptoms include persistent severe abdominal pain, sometimes radiating to the back and accompanied by vomiting), [[hypoglycemia]], [[renal impairment]] (which may sometimes require hemodialysis). The risk of hypoglycemia is increased if the drug is used in combination with [[sulfonylureas]] or [[insulin]].<ref name="pmid24918645">{{cite journal |author=Amblee A |title=Dulaglutide for the treatment of type 2 diabetes |journal=Drugs Today |volume=50 |issue=4 |pages=277–89 |date=April 2014  |pmid=24918645 |doi=10.1358/dot.2014.50.4.2132740 |url=}}</ref><ref name="pmid24485345">{{cite journal |vauthors=Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E |title=Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials |journal=Diabetes Res. Clin. Pract. |volume=103 |issue=2 |pages=269–75 |date=February 2014  |pmid=24485345 |doi=10.1016/j.diabres.2014.01.010 |url=}}</ref>
